Alan Bernstein

Today, we know the most intimate way molecular changes that makes a cancer cell behave differently than a normal cell. We know the mutations in the DNA that are causing these changes, and we know the effects on the proteins that those genes code for. And so now we can design drugs that exploit those changes.

And so if you're a woman with breast cancer, you're gonna be treated, if your cells are HER2 positive, I'm sure every woman knows that phrase, you'll be treated with Herceptin. because we know that molecular difference. If you have chronic myelogenous leukemia, you'll be treated with Gleevec. Or if you have GI stromal cancer, you'll be treated with Gleevec.

And so if you're a woman with breast cancer, you're gonna be treated, if your cells are HER2 positive, I'm sure every woman knows that phrase, you'll be treated with Herceptin. because we know that molecular difference. If you have chronic myelogenous leukemia, you'll be treated with Gleevec. Or if you have GI stromal cancer, you'll be treated with Gleevec.

And so if you're a woman with breast cancer, you're gonna be treated, if your cells are HER2 positive, I'm sure every woman knows that phrase, you'll be treated with Herceptin. because we know that molecular difference. If you have chronic myelogenous leukemia, you'll be treated with Gleevec. Or if you have GI stromal cancer, you'll be treated with Gleevec.

These are all based on information that's come out over the last dozen years or so. Of course, now the big excitement, and not just in cancer, but in other diseases, is using vaccines to treat disease and to prevent disease. So again, these are advances that have happened recently and are on the horizon to continue to happen.

These are all based on information that's come out over the last dozen years or so. Of course, now the big excitement, and not just in cancer, but in other diseases, is using vaccines to treat disease and to prevent disease. So again, these are advances that have happened recently and are on the horizon to continue to happen.

These are all based on information that's come out over the last dozen years or so. Of course, now the big excitement, and not just in cancer, but in other diseases, is using vaccines to treat disease and to prevent disease. So again, these are advances that have happened recently and are on the horizon to continue to happen.

So I'll take in contrast to where cancer research is, which I view as the beachhead disease, if you will. If you think about mental illness, schizophrenia, bipolar disease, we have only very crude tools. to treat those very serious diseases. And the reason is we don't understand those diseases.

So I'll take in contrast to where cancer research is, which I view as the beachhead disease, if you will. If you think about mental illness, schizophrenia, bipolar disease, we have only very crude tools. to treat those very serious diseases. And the reason is we don't understand those diseases.

So I'll take in contrast to where cancer research is, which I view as the beachhead disease, if you will. If you think about mental illness, schizophrenia, bipolar disease, we have only very crude tools. to treat those very serious diseases. And the reason is we don't understand those diseases.

But I think every scientist who's working in the field of biomedical science is optimistic that it is just a matter of time before we will understand really serious diseases like bipolar, depression, Alzheimer's, dementia, and from that will come a whole new class of drugs.

But I think every scientist who's working in the field of biomedical science is optimistic that it is just a matter of time before we will understand really serious diseases like bipolar, depression, Alzheimer's, dementia, and from that will come a whole new class of drugs.

But I think every scientist who's working in the field of biomedical science is optimistic that it is just a matter of time before we will understand really serious diseases like bipolar, depression, Alzheimer's, dementia, and from that will come a whole new class of drugs.

And when that will happen, I don't know, but I think what we have been seeing is an acceleration of new drugs coming on the market because of the advances that have been made at universities and exploited correctly by the pharmaceutical industry. So this is a very exciting time. And so to cut that off would be just a shame, just a shame. Thank you so much for your time today. My pleasure, David.

And when that will happen, I don't know, but I think what we have been seeing is an acceleration of new drugs coming on the market because of the advances that have been made at universities and exploited correctly by the pharmaceutical industry. So this is a very exciting time. And so to cut that off would be just a shame, just a shame. Thank you so much for your time today. My pleasure, David.

And when that will happen, I don't know, but I think what we have been seeing is an acceleration of new drugs coming on the market because of the advances that have been made at universities and exploited correctly by the pharmaceutical industry. So this is a very exciting time. And so to cut that off would be just a shame, just a shame. Thank you so much for your time today. My pleasure, David.